Vertex Pharma (VRTX) Misses Q2 EPS by 113c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Vertex (VRTX) PT Raised to $576 at Wolfe Research
August 5, 2024 5:19 AM EDTWolfe Research analyst Andy Chen raised the price target on Vertex (NASDAQ: VRTX) to $576.00 (from $520.00) while maintaining a Outperform rating.
The analyst comments "Revenue & earnings in-line. Now what after the bull run? Little incremental news aside from two exhibits on T1D. Our... More
